Determination of the Efficacy of Slendertone® Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging

The trial was planned with 100 healthy female volunteers between 25 and 55 years of age.

Treated group: Face device 20 minutes per day, 5 days per week for 12 weeks.

Control group: No NMES.

Both Groups: No changes to usual beauty routine, or use of beauty products with an anti-aging claim, or changes to usual diet or exercise habits over the course of the 12 week study period.

Assessments:

Ultrasound measurements of the zygomaticus major muscle were planned at Baseline, and at the end of Weeks 6 and 12.

Psychometric questionnaires at Baseline, end of Weeks 6 and 12.

Inclusion criteria

• Healthy (by their own report) female participants aged between 35 and 55
• Visual signs of aging of the face
• Able and willing to complete all study assessments and to be followed for the full course of the study.
• Able to read, write and follow instructions in English.
• Able and willing to provide informed consent.

Exclusion criteria

• Pregnant women (or pregnancy within last 3 months).
• Inadequate precaution or procedure to prevent pregnancy (women of child- bearing potential only).
• Individuals who have any implanted medical devices (pacemaker, pump, catheter, etc.)
• Current or history of a medical condition that would contraindicate treatment with the product, such as epilepsy, hernia, abdominal ulcer, diabetes, or other conditions which, in the opinion of the Investigator, would place the participant at risk.
• A current skin disease of any type at the test site (e.g. acne, eczema, psoriasis, burns, abrasions, etc.)
• Heavy alcohol consumption in the opinion of the investigator.
• A fever in the last 12 hours prior to the first application of the test device.
• History of heart disease.
• History of stroke.
• History of malignant disease.
• Insulin dependent diabetes.
• Concurrent medication likely to affect the response to the test article or confuse the results of the study (e.g. routine high dose use of any drugs that may artificially affect skin tone).
• Individuals who are currently participating in any other clinical. investigation, or who have participated in a study with the same indication within 1 year.
• Principal investigator for this study, or member of study staff.
• Individuals who have had facial surgery.
• Individuals who use BOTOX. (The latter two exclusions were applied because of the possibility of an altered anatomical or physiological background which may have interfered with the effectiveness of the treatment).